contents
TRANSCRIPT
REVIEWS
KEYNOTE
116 Mechanistic systems modeling to guide drug discovery and developmentBrian J. Schmidt, Jason A. Papin and Cynthia J. Musante
128 Emergence of zebrafi sh models in oncology for validating novel anticancer drug targets and nanomaterialsMurielle Mimeault and Surinder K. Batra
INFORMATICS
141 A chemistry wiki to facilitate and enhance compound design in drug discoveryGraeme R. Robb, Darren McKerrecher, Nicholas J. Newcombe and Mike J. Waring
POST SCREEN
148 Practical purifi cation of hydrophilic fragments and lead/drug-like molecules by reverse phase fl ash chromatography: tips, tricks and contemporary developmentsAndrew N. Hobbs and Robert J. Young
155 Biomarkers of Parkinson’s disease: current status and future perspectivesJian Wang, Jake G. Hoekstra, Chuantao Zuo, Travis J. Cook and Jing Zhang
163 Orphan drugs: the regulatory environmentPedro Franco
173 PET and SPECT tracers for glutamate receptorsVattoly J. Majo, Jaya Prabhakaran, J. John Mann and J.S. Dileep Kumar
185 Imaging in the cardiovascular and metabolic disease areaRobert A. Comley and David Kallend
193 Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancerDavid Loven, Erez Hasnis, Francesco Bertolini and Yuval Shaked
202 Something’s got to give: psychiatric disease on the rise and novel drug development on the declineDaniel J. Chandler
CONTENTS 1
u
February 2013 Volume 18 Numbers 3/4 pp. 107 – 208
Cover StoryThe leading story of this issue of Drug Discovery Today focuses on large mechanistic models of biological systems, especially those with applications in drug development. They explain that such approaches have demonstrated value to industrial research programs, and they posit that they will become an integral component of research practice as the pharmaceutical industry transitions to increasing utilization of computational approaches as a component of an evolving research paradigm.